Hypnotherapy

Download this page as PDF · Summary

1. What Hypnotherapy Is

Hypnotherapy is a psychotherapeutic method that uses trance states to focus attention and convey suggestions for changes in perception, behaviour, or physiological processes. Originating in the 18th century from mesmerist approaches, it was systematised in the 20th century through clinical psychology and neuroscience. It is delivered by trained therapists who induce an altered state of consciousness via language, imagery, or physical relaxation techniques. Standardised protocols exist for applications such as pain reduction, anxiety management, or gastrointestinal disorders, though session duration and frequency vary.

The central mechanism of action in hypnotherapy involves the modulation of attention and expectation, which is neurobiologically associated with changes in prefrontal, limbic, and sensory brain regions. Studies demonstrate that hypnotic suggestions can influence pain perception, autonomic functions (e.g., bowel motility), and emotional regulation. Measurability is assessed via subjective scales (e.g., pain intensity), physiological markers (e.g., skin conductance), or functional imaging. A key challenge is standardisation: trance induction and suggestions vary in effectiveness between individuals, and therapist dependency complicates reproducibility. Additionally, the lack of uniform definitions for “hypnotic depth” or “responsiveness” hinders comparisons across studies.

2. What the Studies Show in Detail

The foundational human studies and key reviews—organised by application, including population, duration, preparation, outcome measures, and results as reported in the original publications. Figures are included only where explicitly stated in the study.

Distribution of controlled human trials by application—numbers are non-additive as a single study may cover multiple areas:

Bowel and Microbiome

The HT intervention comprised six sessions over three months, combined with home practice. Primary endpoints were pain intensity and frequency, measured via weekly pain diaries. After one year, pain intensity in the HT group decreased from 13.5 to 1.3 points (scale 0–20), and frequency from 13.5 to 1.1 days/week—significantly more than in the SMT group (intensity: 14.1 to 8.0; frequency: 14.4 to 9.3 days/week; p<0.001). Clinically relevant improvement was observed in 54.3% of HT patients vs. 25% of SMT patients. Limitation: No blinding, small sample size 2.

A 2016 RCT compared HT with a low-FODMAP diet in 74 IBS patients. The HT group received one hour of hypnotherapy weekly for six weeks, while the diet group followed strict nutritional guidelines. The primary endpoint was change in overall symptoms (visual analogue scale, VAS) after six weeks. Both groups showed similar improvements (HT: -33 points; diet: -30 points; p=0.67), with ≥20 mm VAS reduction achieved in 72% (HT), 71% (diet), and 72% (combination). After six months, 74% (HT), 82% (diet), and 54% (combination) maintained improvements. HT also led to significantly greater psychological improvements (e.g., anxiety, depression). Limitation: No placebo control for HT, short follow-up.

A long-term follow-up study (2012) examined 52 children from a previous RCT (HT vs. SMT) after an average of 4.8 years. 68% of HT patients remained in remission (vs. 20% in SMT; p=0.005), with significantly lower pain scores (intensity: 2.8 vs. 7.3; frequency: 2.3 vs. 7.1; p<0.01). Somatisation scores also improved (15.2 vs. 22.8; p=0.04). Limitation: Observational design, no re-randomisation.

In an RCT involving 100 therapy-refractory IBS patients (2013), group HT (10 weekly sessions) was compared with SMT. The primary endpoint was improvement in the IBS Impact Scale at 12 months. 54.3% of HT patients vs. 25% of SMT patients showed clinically relevant improvements (p=0.004). HT also led to significant improvements in quality of life and psychological well-being. Limitation: No blinding, high drop-out rate (10%) 7.

An RCT from 2013 tested HT in 54 patients with remitting ulcerative colitis. The HT group received seven sessions over three months. The primary endpoint was the proportion of patients in clinical remission at 52 weeks. 68% of HT patients vs. 40% of controls remained in remission (p=0.04), with a mean remission prolongation of 78 days. No differences were observed in quality of life or medication adherence. Limitation: Small sample size, single-centre study 5.

Hypothesis The data suggest that HT is particularly effective in classic IBS (without dominant psychopathology) and in children/adolescents. The effects appear to be long-term stable, even in therapy-refractory cases. It remains unclear whether HT directly influences gut motility or primarily acts via psychological mechanisms—physiological parameters (e.g., barostat measurements) showed no changes 15.

Missing studies: Long-term data on HT in organic bowel diseases (e.g., Crohn’s disease), direct comparisons with pharmacological therapies (e.g., antidepressants), and investigations into cost-benefit aspects in clinical practice.

Oncology

An RCT from 2008 examined HT in 60 female breast cancer patients with hot flushes. The intervention group received five weekly HT sessions, while controls received no treatment. The primary endpoint was the change in the Hot Flash Score (frequency × severity). After 12 weeks, the score in the HT group reduced by 68% (p<0.001), whereas controls showed no significant change. Secondary improvements were observed in anxiety, depression, and sleep quality. Limitation: No placebo control, short follow-up 3.

In an RCT from 1999, 30 children (aged 5–15) with cancer undergoing bone marrow aspirations were treated with either HT, cognitive behavioural therapy (CBT), or no intervention. HT and CBT significantly reduced pain and anxiety more than the control (p<0.05), with HT leading to fewer behavioural issues. Limitation: Small sample size, no blinding.

An RCT from 2003 tested HT in 80 children (aged 6–16) before lumbar punctures. The HT group (direct or indirect suggestions) showed significantly less pain and anxiety than controls (p<0.05). Hypnotisability correlated with therapeutic success. Limitation: Effects diminished when patients switched to self-hypnosis—the therapist’s presence appears crucial.

Hypothesis HT may be particularly helpful for procedural pain (e.g., punctures) and hot flushes, possibly by reducing anxiety and improving self-regulation. However, the limited data for chronic pain in cancer patients do not yet allow conclusions, and findings on self-reported fatigue scores remain inconclusive. It remains unclear whether HT is similarly effective in adults with advanced tumours as in children.

Missing studies: Comparisons of HT with pharmacological analgesics (e.g., opioids), long-term data on fatigue or quality of life in oncology patients, and investigations into combination therapies (e.g., HT + chemotherapy).

Fatigue and Stress

An RCT from 2013 examined HT in 187 postmenopausal women with ≥7 hot flushes/day. The HT group received five weekly sessions, while controls received structured attention. The primary endpoint was the subjective reduction in hot flushes at 12 weeks. The HT group reduced frequency by 74% (vs. 17% in controls; p<0.001), with improvements in sleep quality and daily impairment. Limitation: No blinding, no physiological measurement of hot flushes 4.

Hypothesis HT might help with subjective stress-related symptoms (e.g., hot flushes, sleep disturbances) by modulating distress perception. However, its impact on autonomic regulation in humans remains untested, and data on self-reported fatigue (e.g., in Long-COVID) or occupational stress are lacking.

Missing studies: Comparisons of HT with relaxation techniques (e.g., progressive muscle relaxation), long-term data on burnout or chronic fatigue syndrome, and investigations into combination therapies (e.g., HT + mindfulness).

Cognition and Psyche

An RCT from 2006 tested HT in 28 patients with non-cardiac chest pain (NCCP). The HT group received 12 sessions over 17 weeks, while controls received supportive therapy plus placebo. The primary endpoint was global pain improvement. 80% of HT patients vs. 23% of controls reported improvement (p=0.008), with a significantly greater reduction in pain intensity (p=0.046). The study showed a potential benefit, but the small sample size and lack of blinding limit the conclusions 6.

In an RCT from 2022, HT was compared with virtual reality (VR) in 100 patients before/after cardiac surgery. The HT group received 20-minute sessions on two days. The primary endpoint was the change in anxiety and pain. Both groups showed anxiety reduction, but no significant differences between HT and VR. Limitation: No placebo control, short intervention.

An observational study from 2003 followed 204 IBS patients for up to six years after HT. 71% initially responded to HT, of whom 81% remained improved long-term. Symptom scores, quality of life measures, and psychological distress showed significant improvements (p<0.001). Limitation: No control group, retrospective data collection 13.

Hypothesis HT appears effective for psychosomatic pain (e.g., NCCP, IBS), possibly by reducing catastrophising and improving pain coping. However, the evidence for trait anxiety or depression in controlled trials is inconsistent—some studies show effects, others do not.

Missing studies: Comparisons of HT with cognitive behavioural therapy (CBT) for anxiety disorders, long-term data on post-traumatic stress disorder (PTSD), and investigations into neurobiological mechanisms (e.g., fMRI studies).

Skin

An observational study from 2002 examined HT in 250 IBS patients (18 of whom underwent additional barostat measurements). Patients received 12 sessions over three months. HT significantly improved all IBS symptoms (p<0.001) but did not alter rectal pain thresholds or gut tone in the measured subgroup. Psychological factors (somatisation, anxiety) improved markedly. Limitation: No control group, no blinding 15.

Hypothesis HT may be effective for skin-related psychosomatic symptoms (e.g., itching, neurodermatitis) by reducing psychological triggers. However, specific studies on skin conditions are lacking.

Missing studies: RCTs on HT for neurodermatitis, psoriasis, or chronic itching, as well as investigations into immunological effects (e.g., cytokine profiles).

Inflammatory Processes

A 2018 review summarises the evidence on psychogastroenterological therapies (including hypnotherapy and other approaches) in inflammatory bowel diseases. In a randomised controlled trial (RCT) on ulcerative colitis included in the review, HT extended remission duration by 78 days (p=0.03) and achieved a higher remission rate after 52 weeks (68% vs. 40%; p=0.04). Potential mechanisms such as stress reduction were observed, while immune modulation remains a hypothesis, as the study did not measure inflammatory markers.

Hypothesis HT may exert effects in chronic inflammatory diseases (e.g., IBS, ulcerative colitis) via psychoneuroimmunological pathways. Research on systemic inflammatory markers (e.g., CRP, cytokines) stands out as a key question for future studies.

Missing studies: RCTs on HT in Crohn’s disease, investigations into molecular mechanisms (e.g., gut microbiome, epigenetics), and long-term data on disease progression.

Overall Picture

Controlled human trials on hypnotherapy (HT) provide robust evidence in gastroenterological applications (particularly IBS): they showed significant improvements in symptoms, quality of life, and psychological distress, with effects lasting for years. HT appeared particularly effective in classic IBS (without dominant psychopathology) and in children/adolescents, whereas older patients (>50 years) or those with atypical symptoms responded less well 14. In oncology, controlled trials showed that HT reduced procedural pain and hot flushes, with stronger effects observed in children than in adults. For psychosomatic pain (e.g., non-cardiac chest pain, NCCP) and stress symptoms (e.g., hot flushes), controlled studies indicated moderate effects, though often without clear superiority over other psychological interventions (e.g., CBT).

The evidence base for chronic inflammatory diseases (e.g., Crohn’s disease), dermatological conditions, or neurological applications (e.g., epilepsy) from controlled human trials is limited or absent. Furthermore, many controlled studies are constrained by small sample sizes, lack of blinding, or short follow-up periods. Systematic comparisons with pharmacological therapies (e.g., antidepressants, antispasmodics) or other non-pharmacological interventions (e.g., acupuncture, diets) are rare. It also remains unclear whether HT directly influences physiological parameters (e.g., gut motility, inflammatory markers) or primarily acts via psychological mechanisms (e.g., stress reduction).

3. How Robust Is the Research?

The research landscape on hypnotherapy is broad but unevenly distributed. The majority of human studies are observational or controlled. Most controlled trials investigate cognitive functions and fatigue, followed by gastrointestinal disorders and oncological applications. Irritable bowel syndrome dominates, with one of the most cited studies dating back to 1984, while other areas, such as cardiovascular diseases or the immune system, are scarcely represented. Reviews focus on mechanisms and meta-analyses, with a systematic review from 2014 receiving the most attention.

The robustness of the data varies considerably. Controlled studies on irritable bowel syndrome and pain show consistent effects, particularly in long-term follow-ups (e.g., 2012: 5-year follow-up in children). Methodological strengths include randomised designs and standardised protocols (e.g., 'gut-directed hypnotherapy'). Weaknesses include small sample sizes, lack of blinding (therapist and patient are usually not blinded), and heterogeneous control conditions (e.g., waitlist vs. active therapy). Observational studies provide indications of long-term effects but cannot establish causality. Basic research suggests neurobiological correlates but often remains correlational.

4. Common Claims—and What the Data Support

5. The Most Robust Studies

Ranked by evidential strength, not by prominence. The full evaluation includes many more studies; these represent the most reliable.

Controlled Human Studies

• 1 Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome (1984)
• 2 Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomised controlled trial (2007)
• 3 Randomised trial of a hypnosis intervention for the treatment of hot flushes among breast cancer survivors (2008)
• Clinical hypnosis versus cognitive behavioural training for pain management in paediatric cancer patients undergoing bone marrow aspirations (1999)
• Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome (2016)
• Long-term follow-up of gut-directed hypnotherapy versus standard care in children with functional abdominal pain or irritable bowel syndrome (2012)
• Psychological treatments for functional gastrointestinal disorders: a primer for the gastroenterologist (2013)
• 4 Clinical hypnosis in the treatment of postmenopausal hot flushes: a randomised controlled trial (2013)
• 5 Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis (2013)
• Clinical hypnosis in the alleviation of procedure-related pain in paediatric oncology patients (2003)
• 6 Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy (2006)
• Integrative medicine therapies for pain management in cancer patients (2019)
• A critical review of approaches to the treatment of dental anxiety in adults (2013)
• 7 Long-term success of gut-directed group hypnotherapy for patients with refractory irritable bowel syndrome: a randomised controlled trial (2013)
• 8 Effects of gut-directed hypnotherapy on IBS in different clinical settings—results from two randomised, controlled trials (2012)
• Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised trial (2020)
• Virtual reality and hypnosis for anxiety and pain management in intensive care units: a prospective randomised trial among cardiac surgery patients (2022)
• 9 Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome (2004)
• Virtual reality hypnosis for pain associated with recovery from physical trauma (2010)
• 10 Hypnosis to manage distress related to medical procedures: a meta-analysis (2008)
• Randomised controlled trial of brief mindfulness training and hypnotic suggestion for acute pain relief in the hospital setting (2017)
• 11 Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial (2019)
• 12 Home-based hypnotherapy self-exercises versus individual hypnotherapy with a therapist for the treatment of paediatric irritable bowel syndrome and functional abdominal pain: a randomised controlled trial (2017)
• Mediators of a brief hypnosis intervention to control side effects in breast surgery patients: response expectancies and emotional distress (2010)

6. Summary

Hypnotherapy (HT) is most robustly evidenced for gastroenterological applications, particularly in irritable bowel syndrome (IBS). Several randomised controlled trials (RCTs) demonstrate significant improvements in symptoms, quality of life, and psychological distress, with effects lasting for years. HT appears to be particularly effective in classic IBS without dominant psychopathology, as well as in children and adolescents. In oncology, HT reduces procedural pain (e.g., aspirations) and hot flushes, with effects more pronounced in children than in adults. For psychosomatic pain (e.g., non-cardiac chest pain) and stress-related symptoms (e.g., postmenopausal hot flushes), HT shows moderate effects, though it often does not clearly outperform other psychological interventions such as cognitive behavioural therapy (CBT).

Hypothesis Hypnotherapy (HT) may induce neurobiological changes in prefrontal, limbic, and sensory brain regions through the modulation of attention and expectation. This could explain why HT is particularly effective in functional disorders (e.g., IBS), where psychological factors play a central role. The long-term effects suggest that HT does not merely act symptomatically but may also sustainably improve self-regulation and pain management. In inflammatory bowel diseases such as ulcerative colitis, HT may exert effects through stress reduction and immune modulation; however, direct measurements of inflammatory markers are lacking. Hypothesis: HT could produce synergistic effects when combined with other therapies (e.g., diets, pharmacotherapy), particularly in treatment-refractory cases. Currently, there is insufficient evidence to assess the efficacy or mechanisms of HT for dermatological or neurological applications.

Future studies should address the following questions: 1) Direct physiological effects: Does HT measurably influence gut motility, inflammatory markers (e.g., CRP, cytokines), or autonomic functions? 2) Comparisons with standard therapies: How does HT perform in direct comparison with pharmacological therapies (e.g., antidepressants, antispasmodics) or other non-pharmacological approaches (e.g., acupuncture, diets)? 3) Long-term data and subgroups: Which patient groups benefit the most (e.g., age, symptom profile, hypnotisability)? 4) Cost-benefit aspects: Is HT cost-effective in clinical practice, particularly for chronic conditions? 5) Mechanisms: Which neurobiological or immunological pathways mediate the effects of HT, and how can these be targeted? 6) Combination therapies: Can HT enhance the efficacy of other therapies (e.g., chemotherapy, mindfulness), and if so, under what conditions?

7. Unresolved Questions

• Neurobiological mechanisms: Which brain regions and neurotransmitters are causally involved in the effects?
• Long-term effects: Do the effects persist for chronic conditions over years, or are booster sessions required?
• Predictors: Can responders be identified in advance (e.g., via suggestibility tests or genetics)?